1[1]Hawkins L K, Lemoine N R, Kim D, et al. Oncolytic biotherapy: a novel therapeutic platform[J]. Lancet Oncology, 2002, 3(1): 17- 26.
2[2]Dalerba P, Maccalli C, Casati C, et al. Immunology and immunotherapy of colorectal cancer[J]. Criti Rev Oncol/Hematol, 2003, 46(1): 33-57.
3[3]Howard C J, Hope JC, Stephens S A, etal. Co-stimulation and modulation of the ensuing immune response [ J ]. Vet Immunol Immunopathol,2002, 87(3-4): 123-130.
4[4]Ashikaga T, Hoya M, Itagaki H, et al. Evaluation of CD86 expression and MHC class Ⅱ molecule internalization in THP-1 human monocyte cells as predictive endpoints for contact sensitizers[J]. Toxicology In Vitro, 2002,16(6): 711 - 716.
5[5]Schott M, Seissler J. Dendritic cell vaccination: new hope for the treatment of metastasized endocrine malignancies [ J ]. Trends Endocrinol Metab,2003, 14(4): 156-162.
6[6]Alessandro D S, Stefania B, Michela P, et al. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix [J]. Gynecol Oncol, 2003, 89(2): 271-280.
7[1]Fields R C, Shimizu K, Mule J J, et al. Murine dendritic cells pulsed with whole tumor lysates mediate potent anti-tumor immune responsesin vitro and in vivo[J]. Proc Natl Acad Sci U S A, 1998, 95(21): 9482 -9487.
8[2]Saha A, Chatterjce S K, Foon K A, et al. Murine dendritic cells pulsed with an anti-idiotype antibody induce antigen-specific protective antitumor immunity[J]. Cancer Res, 2003, 63(11): 2844-2854.
9[3]Engleman E G. Dendritic cell-based cancer immunotherapy[J]. Semin Oncol, 2003, 30(3 Sup pl 8): 23-29.
10[4]Bernadette F, Thomas G B. A method for the production of eryopreserved aliquots of antigen-preloaded, mature dendritic cells ready for clinical use [J]. J Immunol Methods, 2000, 245(1-2): 15-29.
